CADTH has received the following notice(s) of pending drug submission(s).
Brand name
Luxturna
Generic name
voretigene neparvovec
Manufacturer
Novartis Pharmaceuticals Canada Inc.
Indication(s)
Vision loss, inherited retinal dystrophy
Project Number
SR0643-000
Call for patient ...
For the latest updates and guidance on COVID-19, please consult the Public Health Agency of Canada.
As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the risks to our staff and ensure that we continue to support Canada’s health care decision-makers during this period.
Public health authorit...
A new project on Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women is now available for feedback from all interested stakeholders.
Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women
Call for Feedback: 2020-03-05
Feedback Due By: 2020-03-19
Consultation Document: Clinical Report
Product T...
April 18, 2020 - April 21, 2020
A message from Dr. Brian O’Rourke, CADTH President and CEO,
After carefully considering the evolving situation with COVID-19, and keeping in mind the Public Health Agency of Canada’s advice on mass gatherings during the outbreak, we’ve made the difficult decision to cancel our in-person conference, the CADTH Symposium, scheduled to be held in T...
